Dr Ed Carter

Dr Shayin Gibson

Dr Nick Roth

Dr Elena Tomas-Bort

Elena studied Medical Engineering BEng at Queen Mary University of London followed by an MSc in Cancer and Therapeutics at Barts Cancer Institute. She completed her PhD in the Grose lab in 2023, studying purinergic signalling in pancreatic cancer. She is currently working on building a research centre in Spain.

Dr Kubra Yoneten

Kubra obtained her BSc in Biology, Life Sciences from Istanbul University, Turkey. She continued her PhD in Biomedical Engineering to investigate novel biomarkers for breast cancer using proteomic approaches before joining the Barts Cancer Institute in November 2020 where she studied the metabolic stresses accompanying activation of oncogenes. She then joined Grose lab in January 2022 where she studied how ADAMTS14 regulates the behaviour of stellate cells and pancreatic cancer progression.

Dr Lucía Fernández

Lucía obtained her BSc in Pharmacy followed by a MRes in Molecular Approaches in Health Sciences, both from the University of Valencia. She continued there for her PhD in Biomedicine to study how calpains subcellular localization determines their roles in physiological and neoplastic breast models. Lucía joined the Grose lab in 2018 to investigate the crosstalk between luminal and myoepithelial cells in the progression from DCIS to invasive breast cancer.

Dr Demi Wiskerke

Demi obtained her BSc in Archaeological, Anthropological and Forensic Sciences from Bournemouth University followed by an MRes in Cancer Biology from Imperial College London in 2018, after which she joined the Grose lab. For her PhD, she investigated how to circumvent resistance to EGFR targeted therapy in glioblastoma.

Dr Abigail Coetzee

Abbie obtained a BSc in Biomedical Science from the University of Surrey in 2013, which included a placement year at GSK. She then obtained an MSc in Cancer Therapeutics at BCI in 2015, before continuing in the labs of Prof Richard Grose and Prof Hemant Kocher for her PhD project focused on targeting FGFR signalling cross-talk in pancreatic cancer. Abbie now works as post-doctoral researcher as part of Dr Adrian Biddle’s group at the Blizzard Institute.

Dr Natasha Clayton

Natasha joined the Grose lab in 2015 after completing a PhD in Biochemistry at the University of Cambridge. Natasha's postdoctoral research focused on the mechanisms underlying resistance to targeted therapy in cancer. Her work helped to elucidate the role of PHLDA1 downregulation in the development of resistance to receptor tyrosine kinase inhibitors in HER2+ breast cancer and FGFR2-driven endometrial cancer. Natasha is now a Senior Research Associate in Anne Ridley's group at the University of Bristol, focusing on the role of atypical Rho family GTPases in prostate cancer cell migration and metastasis.

Dr Joshua Dawkins

Joshua's doctoral research investigated the roles for two histone methlytransferases in pancreatic cancer. After demonstrating effects on cell cycle regulation and chemotherapy sensitivity, bioinformatic analyses of patient tumours identified their aberration as correlating with survival outcomes. Now he works in the global commercial team of MorphoSys, a biopharmaceutical company based in Munich, Germany. As an associate director of competitive intelligence, Joshua is responsible for sharing insights and implications related to clinical and commercial developments across the sector.

Dr Chris Milton

Chris obtained a BSc in Biology from the University of York, which included a placement at AstraZeneca. He worked at Inpharmatica, followed by the National Institute of Medical Research before conducting a PhD on resistance to PI3K inhibitors in Prof Paul Workman’s lab at the ICR. He continued at the ICR in Prof Jane Shipley’s lab studying FGFRs in paediatric sarcomas before joining the Grose lab in 2019 to investigate mechanisms of FGFR1 controlled invasion in pancreatic cancer.

Dr Luisa Robbez-Masson

Luisa completed her PhD in the Grose lab in 2013 after working on a project focusing on FGFR2 and its role in the development of breast cancer. She is currently working at the Institute of Cancer Research (London) on the early stage of a project based around the concept of “Reverse Translation” from the clinic. Her aim is to use patient’s data in order to shed light on novel resistance mechanisms, particularly to PARP and ATR inhibitors in the context of Triple negative breast cancer.

Dr Athina-Myrto Chioni

Myrto joined Prof R. Grose’s lab in 2006 as a postdoctoral researcher investigating the role of fibroblast growth factor signalling in organogenesis, epithelial development, tissue repair and cancer. In 2014, she joined Kingston University London, where she is now a senior Lecturer in Pathobiology and Cancer Biology and deputy course director for BSc Biomedical Sciences.

Dr Yasmine Tanner

Yasmine’s PhD project was focussing on resistance mechanisms in FGFR-driven cancers using cell-based 3D models such as Alvetex comparing cell signalling in 2D versus 3D with and without stromal support. Currently she is working at Sanofi Pasteur in Switzerland in the vaccines field.

Dr Abbie Fearon

Abbie completed her PhD in the Grose group from 2011 to 2015. Here, she worked on the dissection of drug resistance mechanisms in FGFR2 mutant endometrial cancer. She is now a postdoctoral research scientist working on liver repair and regeneration in the lab of Prof Sabine Werner at ETH, Zürich.